Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma

Leukemia and Lymphoma

Volumn 51, Issue 9, 2010, Pages 1678-1685

  Li, Xing ^a   Lin, Qu ^a   Dong, Min ^a   Wen, Jing Yun ^a   Wei, Li ^a   Ma, Xiao Kun ^a   Chen, Zhan Hong ^a   Wu, Xiang Yuan ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Hepatitis B; lymphoma; rituximab; survival; virus reactivation

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL ARTICLE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG SUBSTITUTION; FEMALE; FOLLICULAR LYMPHOMA; HEPATITIS B; HUMAN; INTERNATIONAL NORMALIZED RATIO; KAPLAN MEIER METHOD; LARGE CELL LYMPHOMA; LIVER INJURY; LYMPHOMA; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL;

ACUTE DISEASE; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; BILIRUBIN; CYCLOPHOSPHAMIDE; DNA, VIRAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER FUNCTION TESTS; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREDNISONE; PROGNOSIS; PROTHROMBIN TIME; SURVIVAL RATE; VINCRISTINE; VIRUS ACTIVATION;

EID: 77956313175     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.499486     Document Type: Article

References (24)

1. Cvetkovic RS, Perry CM. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2006;66:791-820.
2. Vidal L, Gafter-Gvili A, Leibovici L, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2009;101:248-255.
3. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209-220.
4. Wang F, Xu RH, Luo HY, et al. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer 2008;8:115.
5. Liang XF, Chen YS, Wang XJ, et al. [A study on the seroepidemiology of hepatitis B in Chinese population aged over 3-years old]. Chin J Epidemiol 2005;26:655-658. [in Chinese].
6. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001;344:68-69.
7. Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009;90:13-23.
8. Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005;46:1085-1089.
9. Perceau G, Diris N, Estines O, Derancourt C, Levy S, Bernard P. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 2006;155:1053-1056.
10. Sera T, Hiasa Y, Michitaka K, et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006;45:721-724.
11. Tsutsumi Y, Kawamura T, Saitoh S, et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004;45:627-629.
12. Westhoff TH, Jochimsen F, Schmittel A, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003;102:1930.
13. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-276.
14. Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27:605-611.
15. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539.
16. Li YH, He YF, Jiang WQ, et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006;106:1320-1325.
17. Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008;47:844-853.
18. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242.
19. Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology 2005;41:1179-1197.
20. Shen L, Li JQ, Zeng MD, Lu LG, Fan ST, Bao H. Correlation between ultrasonographic and pathologic diagnosis of liver fibrosis due to chronic virus hepatitis. World J Gastroenterol 2006;12:1292-1295.
21. Kami M, Hamaki T, Murashige N, et al. Safety of rituximab in lymphoma patients with hepatitis B or hepatitis-C virus infection. Hematol J 2003;4:159-162.
22. Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepat 2001;8:311-321.
23. Zell JA, Yoon EJ, Ignatius Ou SH, Hoefs JC, Chang JC. Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab. Anticancer Drugs 2005;16:83-85.
24. Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009;94:998-1005.